During a BNN Bloomberg TV interview, Jean-Francois Tardif, founder and portfolio manager of Timelo Investment Management, praised the prospects of Profound Medical (NASDAQ:PROF; TSX:PRN).
“Profound has an FDA-approved device [TULSA-PRO] that treats prostate cancer in a manner differently than has been done in the past,” Mr. Tardif said. “We at Timelo believe that Profound is a promising company.”
TULSA-PRO is a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. It is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.
Also pointing to Profound’s low market cap, Mr. Tardif said the company is at the “hockey stick curve and we believe it will be very successful.”
The interview can be viewed here (Profound comments start at the 4:20min mark).
